Please assess the completion status of the following clinical trial:

Trial Title: A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~Diagnosis of rheumatoid arthritis (RA), according to the American College of Rheumatology/The European League Against Rheumatism (ACR/EULAR) 2010 Rheumatoid Arthritis Classification Criteria with \>=3 months disease duration.~Moderately to severely active RA defined as:~* At least 4 of 68 tender joints and 4 of 66 swollen joints at screening visit.~* High sensitivity C-Reactive Protein (hs-CRP) \>=4 mg/L or Erythrocyte Sedimentation Rate (ESR) \>=28 mm/hr at screening visit.~For the combination stratum:~Participants who had continuous treatment with non-biologic DMARDs other than MTX for at least 12 weeks prior to the randomization and on a stable dose for a minimum of 6 weeks prior to screening.~For the monotherapy stratum:~Participants who per investigator judgment were any of inappropriate, intolerant or inadequate to MTX treatment.~Exclusion criteria:~Participants \<20 years of age. Prior treatment with tumor necrosis factor (TNF) antagonists or any other RA-directed biologic agents without the appropriate off-drug period prior to screening.~Prior treatment with anti-interleukin-6 (anti-IL-6) or anti-interleukin-6 receptor (IL-6R) antagonist therapies, including but not limited to tocilizumab or sarilumab.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sarilumab 150 mg q2w + DMARDs (Type: EXPERIMENTAL): Participants received sarilumab 150 mg, subcutaneous (SC) injection, once every two weeks (q2w) along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
- Sarilumab 200 mg q2w + DMARDs (Type: EXPERIMENTAL): Participants received sarilumab 200 mg, SC injection, q2w along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
- Sarilumab 150 mg q2w (Type: EXPERIMENTAL): Participants received sarilumab 150 mg, SC injection, q2w for up to 52 weeks.
- Sarilumab 200 mg q2w (Type: EXPERIMENTAL): Participants received sarilumab 200 mg, SC injection, q2w for up to 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).